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Abstract  
Whether different definitions of metabolic syndrome (MtS) are differently associated with 
colorectal adenocarcinoma (CA) by anatomical location is unclear. A population-based 
cohort study in Norway (CONOR) was conducted from 1995 to 2010. Anthropometric 
measurements, blood samples and lifestyle data were collected at recruitment. CAs were 
identified through linkage to the Norwegian Cancer Register. A composite index of MtS 
defined by the International Diabetes Federation (IDF) or/and the National Cholesterol 
Education Program’s Adult Treatment Panel III (ATP III) and single components of MtS, 
including anthropometrics, blood pressure, lipids, triglycerides, and glucose were analyzed. 
Cox proportional hazards regression was performed to estimate hazard ratios (HRs) and 95% 
confidence intervals (CIs). Significant associations between single metabolic components and 
CA, except reduced high-density lipoprotein cholesterol and non-fasting glucose, were 
observed. MtS defined by two criteria separately showed a similar association with CA in 
general and MtS defined by both IDF and ATP III showed consistent results. Stronger 
associations were observed in the proximal colon in men (IDF HR=1.51, 95% CI: 1.24, 1.84; 
ATP III HR= 1.40, 95% CI: 1.15, 1.70), and the rectum in women (IDF HR=1.42, 95% CI: 
1.07, 1.89; ATP III HR= 1.43, 95% CI: 1.08, 1.90).  
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Abbreviations: 
IDF: the International Diabetes Federation definition 
ATP III:  the National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) 
WHO:  the World Health Organization 
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CONOR: The Cohort of Norway 
HDL: High-density lipoprotein  
SBP: systolic blood pressure 
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Introduction: 
Metabolic syndrome, as assessed according to current international definitions by the key 
components central obesity, dyslipidemia, elevated blood pressure, and abnormal glucose 
metabolism, is associated with colorectal cancer in accumulating studies(1, 2). The definition 
of metabolic syndrome varies, however, which may indicate that the associations might be 
dissimilar. The three widely used definitions for metabolic syndrome are: a) the new 
International Diabetes Federation (IDF) definition; b) the National Cholesterol Education 
Program’s Adult Treatment Panel III (ATP III) definition; c) the WHO (World Health 
Organization) clinical criteria for metabolic syndrome. Although several previous studies 
have demonstrated the positive association between metabolic syndrome and colorectal 
cancer risk (2-5), only one has investigated metabolic syndrome defined by different criteria 
in this context (4). Single components differ slightly in the different definitions of metabolic 
syndrome. It remains inconsistent, though, to what extent single components by different 
definitions account for such an association (4, 6-9). Furthermore, some studies found 
metabolic syndrome was only associated with colorectal cancer in men (6, 10), but others 
demonstrated the opposite (11). Due to the distinct sex-specific incidence pattern of 
colorectal adenocarcinoma in the proximal colon, distal colon and rectum, previous studies 
without examination by anatomical locations may have confounded the sex-specific 
association with metabolic syndrome and/or its single components. Most previous studies 
have analysed the colon and rectum separately, but omitted the distinction between the 
proximal and distal colon, which warrants further investigations. 
In the current study, we examined the association of metabolic syndrome, based on different 
definitions, with a risk of colorectal cancer in the Cohort of Norway study (CONOR), a large, 
prospective population-based cohort in Norway. Since adenocarcinoma is the main 
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histological type of neoplasm in the colon and rectum (more than 90%), the study focuses on 
colorectal adenocarcinoma.  
Materials and Methods 
Study population 
Study design and data collection in the CONOR study has been described in detail 
elsewhere(12). In summary, CONOR is a research collaboration between the Norwegian 
Institute of Public Health and the Universities of Bergen, Oslo, Tromsø, and Trondheim 
(Norwegian University of Science and Technology) from 1995 to 2010. Merging data from 
10 epidemiological studies, CONOR was established as a national database to study risk 
factors of a wide range of diseases. In a recent cohort profile, the locations of these 10 study 
sites in Norway and the websites of each participating cohort are described (12). Letters of 
invitation were mailed approximately two weeks before the time of appointment. In total, 309 
832 individuals were invited and 180 553 participated. Participants underwent a physical 
examination and a non-fasting blood sample was drawn at the screening. After excluding 
participants who were included in two rounds of surveys (7310), prevalent cancer cases 
(6075), those missing anthropometric data (21 234), and those missing daily smoking status 
(1551), 143 477 remained for the final analysis.  
 
Identification of colorectal cancer cases 
Using the unique 11-digit Norwegian citizens’ national identity number, the CONOR cohort 
was followed-up through linkage to the Norwegian Cancer Register and Statistics Norway. 
Colorectal cancer was identified from the Cancer Register according to the International 
Classification of Diseases, 7th edition. The colorectal cancer codes by anatomical location 
included: proximal colon (the cecum, ascending colon, transverse colon, hepatic flexure, the 
splenic flexure and appendix): 1530 and 1531, distal colon (the descending colon, the 
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sigmoid colon): 1532, 1533, and 1534, and rectum: 1540.  Each cohort participant was 
considered at risk from enrollment in the cohort until a diagnosis of colorectal cancer, death, 
being censored (e.g. lost to follow-up, emigration, diagnosis of other malignancies), or end of 
follow-up on December 31, 2010, whichever came first. 
 
The Regional Committee for Medical and Health Research Ethics, Central Norway (ID: 
2012/853/REK midt) approved the current study. All the individual studies included in 
CONOR were approved by their respective ethics committees in different areas. All 
participants signed an informed consent form.    
 
Assessment of the metabolic syndrome components  
Whole blood (5-7 ml) was collected from the participants, and serum was separated by 
centrifuging at the screening site. All laboratory assessments in CONOR were performed at 
the Department of Clinical Chemistry, Oslo University Hospital, Ullevål, except for HUNT II 
(The second Nord-Trøndelag Health Study) where the analyses were performed at the 
Department of Clinical Chemistry, Levanger Hospital, Levanger. Non-fasting serum total and 
High-density lipoprotein (HDL) cholesterol, glucose, and triglycerides were measured 
directly by an enzymatic method (Boehringer 148393, Boehringer Mannheim, Federal 
Republic of Germany - from 2000 onwards Hitachi 917 auto analyzer, Roche Diagnostic, 
Switzerland). An acceptable stability of the laboratory analyses over time in the population 
surveys has been reported(13).  
 
Blood pressure and heart rate were measured by all the CONOR studies at dedicated research 
clinics. Three measurements were recorded and the mean value was calculated based on the 
second and third measurements (14). The stability of the blood pressure measures has been 
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evaluated as acceptable(15). Waist circumference was measured at the umbilicus to the 
nearest centimeter and with the subject standing and breathing normally. Hip circumference 
was measured as the maximum circumference around the buttocks. Waist to hip ratio was 
calculated from measurements of waist versus hip circumference. Body weight (in kilograms, 
to one decimal place) and height (in centimeters, to one decimal place) was measured with 
the participants wearing light clothing without shoes. The measurements were manually 
recorded until the year 2000 and, after that, an electronic height and weight scale was used.  
Body mass index (BMI) was calculated as body weight (kilograms) divided by the square of 
height (meters square). The use of lipid-lowering or anti-hypertensive drugs was collected 
through self-reported data.  
 
Definition of the metabolic syndrome 
Based on the available data in CONOR, two definitions of the metabolic syndrome, the IDF 
and the ATP III, were analyzed and compared (Table 1) (16, 17). The WHO criteria included 
components of impaired glucose tolerance, impaired fasting glucose, or insulin resistance, 
which were not available or not computable in this study. Thus, analysis of the overall 
definition of metabolic syndrome based on the WHO criteria was omitted, but accessible 
single components were analyzed, including waist to hip ratio (men ≥0.90, women ≥0.85), 
reduced HDL (men <0.9 mmol/L, women <1.0 mmol/L), hypertension (systolic blood 
pressure (SBP) ≥140mmHg or diastolic blood pressure (DBP) ≥90 mmHg), and raised fasting 
glucose (≥6.1 mmol/L). 
 
According to the IDF definition(17, 18), a person with metabolic syndrome has central 
obesity (waist circumference based on European standards (men ≥94 cm, women ≥80 cm 
or BMI ≥30) plus any two of the following four factors: 1) raised triglyceride level (≥1.7 
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mmol/L) or use of lipid-lowering drugs; 2) reduced HDL cholesterol (men <1.03mmol/L, 
women <1.29 mmol/L); 3) raised blood pressure (SBP ≥130 mmHg, DBP ≥85 mmHg or 
use of antihypertensive drugs), and 4) raised fasting plasma glucose (≥5.6 mmol/L) (Table 
1). Raised fasting glucose was defined by plasma glucose level and a diagnosis of diabetes. 
Since blood samples were collected based on non-fasting status (time from last meal changed 
from two to eight hours), these results might not reflect the real fasting glucose level.  
According to the ATP III criteria, a person with metabolic syndrome has three or more of the 
single components: 1) central obesity (men ≥102 cm, women ≥88 cm); 2) hypertension 
(SBP ≥130 mmHg, DBP ≥85 mmHg or use of antihypertensive drugs); 3) 
hypertriglyceridemia (≥1.7 mmol/L), reduced HDL cholesterol (men <1.03, women <1.29), 
and elevated fasting glucose (≥5.6 mmol/L) (Table 1)(16). 
 
Statistical analysis 
Cox proportional hazard models were used to estimate the hazard ratios (HRs) and 95% 
confidence intervals (95% CIs).  Associations between single metabolic syndrome 
components, the overall metabolic syndrome definition, use of IDF and ATP III criteria, and 
colorectal cancer by anatomical location were computed.  All of the variables were analyzed 
based on categorical status. 
 
Each single component of the metabolic syndrome was analyzed based on a crude model 
adjusted for age and sex, and a multivariable model adjusted for potential confounders. Since 
the results based on the crude and the multivariable models were not materially different, 
only the multivariable analyses were reported. Confounders were chosen based on previous 
etiological studies on colorectal cancer together with stepwise selection approaches. The 
following co-variables were included in the final model: age (<50, 50-60, ≥60), education 
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(none/primary school/secondary school, high school, university), daily smoking status 
(never/seldom, current), alcohol consumption (never/seldom, about once a week, 2-3 times 
per month, about once a week, several times per week), physical activity (hours per week: 
none, <1, 1-2, ≥3. Further analyses of anthropometric measurements were stratified by sex. 
 
In sensitivity analyses, we excluded the first two years of follow-up in order to decrease the 
potential bias of reverse causality. Age was categorized into more refined groups (<40, 40-44, 
45-49, 50-54, etc.) and analyzed in the multivariate model for the additional analysis. Since 
the results were not materially changed, we only showed it in Web Table 1. For missing 
values, we treated the variables in two different ways: 1) deleted the missing values, or, 2) 
treated a missing value as one category. Since the final results did not change materially, we 
chose either approach depending on the percentage of missing values in the relevant 
variables. Therefore, in the final analysis, smoking status missing values were deleted (1551, 
0.89%) and the missing values of other variables were kept as a category. The proportional 
hazards assumption for the Cox regression model was tested on the basis of Schoenfeld 
residuals. All of the variables did not violate the assumption except age groups that were 
treated as a strata factor in the final model. A two-sided test with a significance level (α) of 
0.05 was chosen. All analyses were performed using SAS 9.3 for Windows (SAS Institute 
Inc., Cary, North Carolina, USA) and Stata 13.0 (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP).  
 
Results 
Population  
With an average 11.3 years of follow-up, 2044 colorectal adenocarcinomas were identified 
from the total cohort (Table 2). In metabolic syndrome defined by IDF (43775), ATP III 
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(40234), or both (31500), 927, 823 and 695 colorectal adenocarcinomas were identified, 
respectively.  Men had a higher incidence of adenocarcinoma in the distal colon (54.8%) and 
rectum (61.8 %), while women had a higher incidence in the proximal colon (51.9 %). The 
mean age in proximal colon cases (65.8 years) was slightly higher than in cases in the distal 
colon and rectum (63.4 and 63.5 years, respectively). Smoking and alcohol consumption 
(several times per week) seemed to be more frequent in rectal adenocarcinoma cases. 
Comorbidity (diabetes, cardiovascular diseases and asthma) was more prevalent in proximal 
adenocarcinoma cases (Table 2).  
 
Single components of the metabolic syndrome  
The risk of colorectal adenocarcinoma was increased by about 20% with both the European 
(men ≥94cm, women ≥80cm) and US (the United States) (men ≥102cm, women ≥88cm) 
definitions of central obesity using waist circumference (Table 3). The risk was mainly 
increased in the colon and not in the rectum. When central obesity was indirectly defined by 
BMI ≥30, the risk attenuated (16%). Increased waist to hip ratio showed similar results as 
waist circumference.  
 
There was a marginally increased risk of colorectal adenocarcinoma (12%) with a higher 
triglycerides level (≥1.7 mmol/L compared with <1.7 mmol/L) (Table 3). However, lipid-
lowering drugs seemed to potentially protect against colorectal adenocarcinoma, especially in 
the distal colon (HR=0.63, 95% CI: 0.42, 0.95) (Table 3). Reduced HDL cholesterol did not 
show a significant association with colorectal adenocarcinoma based on two categorizations 
(Table 3). 
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Raised blood pressure combined with the use of antihypertensive drugs was associated with 
an 18% and 13% increased risk of colorectal adenocarcinoma, using the IDF/ATP III 
definitions or the WHO definition of hypertension, respectively (Table 3).   
 
Raised glucose levels were not associated with colorectal adenocarcinoma, however, self-
reported diabetes increased the risk of colorectal adenocarcinoma by 36%, mainly in the 
proximal colon with 49% (Table 3).   
 
Comparison of the IDF and ATP III definitions for metabolic syndrome 
Both the IDF and ATP III definitions for metabolic syndrome showed positive associations 
with overall colorectal adenocarcinoma, regardless of sex (Tables 4). The IDF definition 
displayed slightly higher HRs than the ATP III definition regarding colorectal 
adenocarcinoma in general (IDF HR=1.24, 95% CI: 1.13, 1.36; ATP III HR=1.17, 95% CI: 
1.07, 1.28). Both were consistently associated with proximal colon adenocarcinoma, 
especially in men (IDF: HR=1.51, 95% CI: 1.24, 1.84; ATP III: HR=1.40, 95% CI: 1.15, 
1.70), and rectal adenocarcinoma in women (IDF: HR=1.42, 95% CI: 1.07, 1.89; ATP III: 
HR= 1.43, 95% CI: 1.08, 1.90), which was not indicated by the single components. 
 
When assessing individuals classified with metabolic syndrome by both definitions 
(metabolic syndrome defined by IDF and ATP III), we also found an increased risk of 
colorectal adenocarcinoma overall (HR=1.26, 95% CI: 1.14, 1.40) (Table 5).  Metabolic 
syndrome defined by both definitions was associated with an increased risk of 
adenocarcinoma in the proximal colon, especially in men (HR= 1.63, 95% CI: 1.30, 2.03 in 
men; HR=1.24, 95%CI: 1.00, 1.54 in women). Similar to results of the separate metabolic 
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syndrome definitions (Table 4), the increased risk of adenocarcinoma in the rectum in women 
was still apparent (HR=1.52, 95% CI: 1.13, 2.06).  
 
We also investigated how central obesity played a role in the definitions of metabolic 
syndrome on the risk of colorectal adenocarcinoma, compared with non-central obesity 
(Figures 1 and 2, see also Web Tables 2 and 3). The results in both figures showed that 
central obesity alone was not associated with an increased risk of colorectal adenocarcinoma, 
while metabolic syndrome with central obesity was. The association was quite consistent 
with the aforementioned results in Tables 4 and 5. However, we also observed two 
exceptional results in men: First, central obesity was negatively associated with rectal 
adenocarcinoma based on the IDF criteria (Figure 1). Second, central obesity alone seemed to 
be associated with a 60% increased risk of adenocarcinoma in the distal colon (Figure 2) 
when using the ATP III definition. Since the definition of central obesity is different in the 
IDF and ATP III criteria, these results may need to be further interpreted based on the 
specific definitions. 
 
Discussion 
The current study found that the metabolic syndrome as a composite index defined by IDF, 
ATP III, or both, and single components of metabolic syndrome, e.g., central obesity, raised 
triglycerides and raised blood pressure, were associated with an increased risk of colorectal 
adenocarcinoma in general. Metabolic syndrome with central obesity contributes to the 
development of colorectal adenocarcinoma. The association of metabolic syndrome as a 
composite index was more prominent with adenocarcinoma of the proximal colon in men and 
rectal adenocarcinoma in women.  
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The strength of this study includes the large prospective cohort with a high number of 
colorectal adenocarcinoma cases. Moreover, the anthropometric data were measured 
objectively by standardized protocols at baseline. Furthermore, blood samples were collected 
and lipid levels were measured by standard procedures. A weakness is that the blood samples 
were not collected in fasting status, so fasting glucose was not available. However, data of 
prevalent diabetes were collected. In addition, the use of lipid-lowering drugs or anti-
hypertensive drugs was collected through self-reported data, which might not cover the 
complete medications information. Another weakness is the lack of detailed information on 
food/nutrients intake, which may result in residual confounding.  
In the current study, single components of the metabolic syndrome, including central obesity, 
raised triglycerides and raised blood pressure, showed positive associations with colorectal 
adenocarcinoma especially in the proximal colon, although some components displayed a 
stronger relation. In the Women’s Health Initiative, a positive association of the metabolic 
syndrome with colorectal cancer was largely accounted for by serum glucose levels and 
SBP(5). In the Physicians’ Health Study (male participants with 494 colorectal cancer cases), 
being overweight and diabetes were associated with an increased risk of colorectal cancer, 
but not elevated blood pressure and hypercholesterolemia(3). In the European Prospective 
Investigation into Cancer and Nutrition, abnormal glucose metabolism and/or central obesity 
were regarded as the main contributors of metabolic syndrome which were associated with an 
increased risk of colorectal cancer(4). Recent studies have demonstrated that central obesity 
may primarily account for this association (5, 8, 19). This is consistent with our results. More 
interestingly, our results showed that central obesity alone was associated with an increased 
risk of adenocarcinoma in the distal colon in men based on the ATP III criteria, but a 
decreased risk of rectal adenocarcinoma based on the IDF definition. As the definition of 
central obesity is more stringent in the ATP III criteria, it indicates that central obesity might 
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be an independent risk factor for distal colon adenocarcinoma. Furthermore, people who have 
central obesity but no metabolic syndrome in the IDF definition are most likely obese, but 
metabolically healthy individuals. This indicates that obesity but a metabolically heathy 
status might be associated with a reduced risk of rectal adenocarcinoma in men. The 
underlying mechanism is, however, unclear.  
The other single components of the metabolic syndrome are more or less related with, or a 
consequence of, central obesity (20, 21). Waist circumference, a surrogate measure of 
visceral adipose tissue, is the commonly used index for central obesity. Visceral adipose 
tissue is physiologically more active than subcutaneous adipose tissue and generates 
hormones and cytokines with inflammatory, metabolic, and direct carcinogenic potential, 
which may directly or indirectly increase colorectal cancer risk(22). Current evidence 
suggests that obesity acts as a risk factor for colorectal cancer by several mechanisms, 
including chronic low-grade inflammation, hyperinsulinemia, as well as alterations in insulin-
like growth factor and adipokine concentrations(22, 23). Specific molecules derived from the 
visceral adipose tissue, including adiponectin, leptin and resistin, are able to establish a 
positive feedback loop, thus increasing the pro-inflammatory and insulin-resistant state and 
promoting tumorigenesis (22, 24). The metabolic syndrome may be a marker of a physiologic 
milieu of growth that encourages tumor initiation, promotion, and progression. 
Previous studies have found that the metabolic syndrome is associated with colorectal cancer 
in men but not in women, but the results are largely inconsistent (4-6, 10, 25, 26). The present 
study found significant associations for both sexes, but also sex-specific associations, e.g., a 
stronger association for rectal adenocarcinoma in women, which is consistent with a recent 
meta-analysis(19, 27). Another study found that only high levels of metabolic factors confer 
an increased risk (7). However, in the present study, a lower level of waist circumference 
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(based on the European definition) conferred a more evident association. A negative 
association between the use of lipid-lowering drugs and distal colon adenocarcinoma was 
observed. This was actually consistent with previous studies regarding the potential negative 
association of lipid-lowering drugs with cancer, e.g., statins(28).   
Few studies have compared the risk of colorectal adenocarcinoma by anatomical locations 
using the single components, or composite index of the metabolic syndrome defined by IDF 
or ATP III, or the metabolic syndrome defined by both. Our findings regarding a significant 
association of metabolic syndrome with proximal colon cancer were consistent with previous 
studies (29, 30). Furthermore, the current study observed a significant association between 
the metabolic syndrome as a composite index with rectal adenocarcinoma in women, which 
was actually not obvious for single components. The distinct incidence pattern of colorectal 
adenocarcinoma by anatomical locations, e.g., female predominance in the proximal colon, 
male predominance in the distal colon and rectum, and older age-specific incidence in the 
proximal colon may indicate etiological differences. The proximal colon might be more 
influenced by internal disorders of metabolic factors, especially sex hormones, which are 
different in obese women and men. A hypothesis raised by McMichael and Potter in the 
1980s considered that sex hormones may alter bile acid synthesis, which possibly acts in a 
more concentrated manner on the proximal colon where fecal bile acids are reabsorbed(31). 
Experimental studies have also demonstrated a remarkable difference in the expression 
pattern of genes according to the anatomical location of colorectal cancer, which may 
interpret the stronger association of metabolic syndrome with adenocarcinoma in the 
proximal colon in the current study(32). By contrast, adenocarcinoma in the distal colon and 
rectum seemed to be affected more evidently by factors involved in energy balance, such as 
obesity, physical activities, diet and gut microbiota. A recent meta-analysis found that 
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physical activity was differently associated with cancer in the colon and the rectum, although 
no difference between the colonic subsites was observed (33).  
In summary, the metabolic syndrome and its components were associated with an increased 
risk of colorectal adenocarcinoma, especially in the proximal colon in men and the rectum in 
women. Central obesity may play a pivotal role connected with other components. 
Understanding the links of metabolic syndrome and its components to carcinogenesis has a 
major clinical significance and may have profound health benefits on colorectal cancer, 
which represents an important cause of mortality and morbidity in our societies.  
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Table 1: Components of the metabolic syndrome and definitions by IDF
*
 and ATP III
#
 
    
Category IDFa   ATP IIIb 
Central obesity    
  Waist circumference ≥94 cm for Europid men; ≥80 cm for Europid 
women; ethnicity-specific values for other 
groups 
 Men >102 cm (>40 in); women >88cm 
(>35in) 
    
  Body mass index
c
 If BMI >30  central obesity can be assumed 
and waist circumference does not need to be 
measured 
  
    
Raised triglycerides ≥150 mg/dL (≥1.7 mmol/L); or specific 
treatment for this lipid abnormality 
 ≥150 mg/dL (≥1.7 mmol/L)  
    
Reduced HDL
d
 cholesterol <40 mg/dL (<1.03 mmol/L) in men; < 50 
mg/dL (<1.29 mmol/L) in women; or specific 
treatment for this lipid abnormality 
 <40 mg/dL (<1.03 mmol/L) in men; <50 
mg/dL (<1.29 mmol/L) in women 
    
Raised blood pressure Systolic blood pressure ≥ 130 mmHg; or 
diastolic blood pressure ≥ 85 mm Hg; or 
treatment of previously diagnosed 
hypertension 
 Systolic blood pressure ≥ 130 mmHg; or 
diastolic blood pressure ≥ 85 mmHg; or 
use of blood pressure lowering agents 
    
    
Raised fasting plasma glucose Fasting glucose ≥100 mg/dL (≥5.6 mmol/L); 
or previously diagnosed type 2 diabetes; If 
≥100 mg/dL (≥5.6 mmol/L), OGTT
e
 is 
strongly recommended but is not necessary to 
define presence of the syndrome 
 Fasting glucose ≥ 100 mg/dL; or use of 
glucose lowering agents. 
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Definition of metabolic syndrome Central obesity (defined as waist 
circumference with ethnicity specific values) 
plus any two of the other above four factors 
  Complying three or more above 
abnormalities 
 
a 
IDF: International Diabetes Federation; bATP III: the National Cholesterol Education Program’s Adult Treatment Panel III. c Body mass index (BMI) 
presented as kg/m
2; d HDL: High-density lipoprotein; 
e
OGTT: oral glucose challenge test. 
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Table 2. Characteristics of colorectal adenocarcinoma cases and cohort participants in CONOR, Norway, 1995-2010 
Variables 
Cohort participants 
(n=143 477) 
Colorectal adenocarcinoma 
(n=2044) 
Colon   
Rectum (n=555) Proximal 
colon 
(n=853) 
 
Distal colon 
(n=606)  
No. % No. % No. % No. % No. % 
Sex 
         
 Men 70033 48.81 1101 53.86 410 48.07 332 54.79 343 61.80 
Women 73444 51.19 943 46.14 443 51.93 274 45.21 212 38.20 
          
 Age at examination  
         
 Mean (Standard 
deviation) 
50.9 (15.5)
a
 64.5(11.8)
 a 
  65.8(11.4)
 a
 63.4(11.8)
 a 
 63.5(12.2)
 a
 
Age by groups 
         
 <50 81232 56.62 341 16.68 119 13.95 117 19.31 103 18.56 
50-59 17559 12.24 269 13.16 96 11.25 91 15.02 80 14.41 
≥60 44686 31.15 1434 70.16 638 74.79 398 65.68 372 67.03 
Education, n(%) 
         
 
None/primary 
school/Secondary school 
32423 22.60 724 35.42 320 37.51 198 32.67 198 35.68 
High school 44964 31.34 468 22.90 193 22.63 136 22.44 134 24.14 
University 29227 20.37 237 11.59 88 10.32 94 15.51 51 9.19 
Missing 36863 25.69 615 30.09 252 29.54 178 29.37 172 30.99 
          
 
Smoking status 
         
 Not daily smoker 101,341 70.63 1542 75.44 653 76.55 461 76.07 402 72.43 
Daily smoker 42,136 29.37 502 24.56 200 23.45 145 23.93 153 27.57 
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Alcohol consumption 
last year          
 Never/seldom 41,694 29.06 690 33.76 316 37.05 182 30.03 185 33.33 
About 1-3 times per 
month 
45,233 31.53 465 22.75 174 20.40 149 24.59 135 24.32 
About once a week 26,106 18.20 331 16.19 123 14.42 116 19.14 89 16.04 
Several times per week 17,187 11.98 265 12.96 104 12.19 77 12.71 80 14.41 
Missing 13,257 9.24 293 14.33 136 15.94 82 13.53 66 11.89 
          
 
Physical activity 
         
 None 43,492 30.31 720 35.23 318 37.28 225 37.13 167 30.09 
Less than once a week  30,222 21.06 342 16.73 117 13.72 108 17.82 113 20.36 
1-2 hours per week 28,226 19.67 284 13.89 113 13.25 86 14.19 84 15.14 
3 or more hours per 
week  
15,581 10.86 129 6.31 49 5.74 41 6.77 36 6.49 
Missing 25,956 18.09 569 27.84 256 30.01 146 24.09 155 27.93 
          
 b Family history of 
cancer 
36,309 25.31 672 32.88 385 45.13 211 34.82 169 30.45 
Diabetes 4463 3.11 122 5.97 57 6.68 31 5.12 33 5.95 
c 
Cardiovascular diseases 11,373 7.93 301 14.73 137 16.06 78 12.87 81 14.59 
Asthma 12,087 8.42 210 10.27 99 11.61 62 10.23 46 8.29 
                      
a Given as mean (standard deviation); b Family history of cancer: self-reported cancer among parents, siblings and children; c Cardiovascular diseases: including angina pectoris, myocardial 
infarction and stroke. 
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Table 3: Single components of the metabolic syndrome and risk of colorectal adenocarcinoma by anatomical locations, the CONOR study, 1995-2010
a
 
Components of metabolic 
syndrome 
Colorectal adenocarcinoma by anatomical locations 
  
Colorectum Proximal Colon Distal Colon Rectum   
No.    % HR 95%CI No.     % HR 95%CI No.     % HR 95%CI No.     % HR 95%CI 
Central obesity 
  
  
  
  
  
  
  
 
 Waist circumference (cm) 
                bMen<94, women <80 816 39.9 Referent 
 
310 36 Referent 
 
243 40.1 Referent 
 
248 44.7 Referent 
 Men≥94, women ≥80 1228 60.1 1.20 1.07,1.35 543 64 1.40 1.17,1.69 363 59.9 1.21 0.98,1.50 307 55.3 0.98 0.79,1.23 
                
 
c
Men<102, women<88 1409 31.1 Referent 
 
566 66 Referent 
 
422 69.6 Referent 
 
401 72.3 Referent 
 
Men≥102, women≥88 635 68.9 1.22 1.07,1.39 287 34 1.25 1.03,1.53 184 30.4 1.20 0.95,1.53 154 27.7 1.14 0.88,1.47 
                
 
b
Body mass index (BMI)
               
 
BMI<30 1611 21.2 Referent 
 
667 78 Referent 
 
480 79.2 Referent 
 
438 78.9 Referent 
 
BMI≥30 433 78.8 1.16 1.04,1.29 186 22 1.15 0.97,1.35 126 20.8 1.16 0.95,1.41 117 21.1 1.20 0.98,1.48 
                
 
d
Waist to hip ratio (WHR)
               
 
Men<0.90, women<0.85 996 48.6 Referent 
 
412 48 Referent 
 
298 49.3 Referent 
 
270 48.7 Referent 
 
Men≥0.90, women≥0.85 1047 51.3 1.23 1.12,1.35 441 52 1.34 1.16,1.55 307 50.7 1.23 1.03,1.47 285 51.3 1.11 0.93,1.33 
                
 
Raised triglycerides
               
 
b,c
Triglycerides (mmol/L) 
               
 
<1.7  1078 52.8 Referent 
 
438 51 Referent 
 
333 55.1 Referent 
 
288 51.9 Referent 
 
≥1.7 962 47.2 1.12 1.02,1.22 414 49 1.18 1.03,1.36 271 44.9 1.04 0.88,1.22 267 48.1 1.13 0.95,1.34 
                
 
Use of lipids lowering drugs
               
 
No 616 83.6 Referent 
 
233 81 Referent 
 
189 87.5 Referent 
 
184 84.8 Referent 
 
Yes 121 16.4 0.86 0.70,1.04 56 19 1.01 0.76,1.36 27 12.5 0.63 0.42,0.95 33 15.2 0.80 0.55,1.16 
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b,c
Raised triglycerides
               
 
No 1010 49.5 Referent 
 
408 48 Referent 
 
316 52.2 Referent 
 
270 48.7 Referent 
 
Yes 1032 50.5 1.11 1.02,1.21 445 52 1.19 1.04,1.36 289 47.8 1.02 0.87,1.20 285 51.3 1.12 0.94.1.32 
Reduced HDL 
               
 
HDL-cholesterol (mmol/L) 
               
 
b,c
Men≥1.03, women≥1.29  1475 72.3 Referent 
 
613 72 Referent 
 
440 72.9 Referent 
 
399 71.9 Referent 
 
Men<1.03, women<1.29 565 27.7 1.07 0.97,1.18 239 28 1.08 0.92,1.25 164 27.1 1.04 0.87,1.25 156 28.1 1.09 0.90.1.31 
                
 
d
Men≥0.9, women≥1.0 1878 92.1 Referent 
 
781 92 Referent 
 
559 92.6 Referent 
 
510 91.9 Referent 
 
Men<0.9, women<1.0 162 7.9 1.08 0.92,1.27 71 8.3 1.17 0.91,1.49 45 7.4 1.01 0.74,1.37 45 8.1 1.06 0.78,1.44 
                
 
Raised blood pressure
               
 
SBP (mmHg) 
               
 
b,c
 <130 530 25.9 Referent 
 
214 25 Referent 
 
168 27.7 Referent 
 
144 26 Referent 
 
≥ 130 1514 74.1 1.17 1.06,1.30 639 75 1.14 0.97,1.35 438 72.3 1.15 0.95,1.39 411 74 1.20 0.99,1.47 
                
 
d
<140 917 44.9 Referent 
 
387 45 Referent 
 
282 46.5 Referent 
 
239 43.1 Referent 
 
≥ 140 1127 55.1 1.11 1.01,1.22 466 55 1.00 0.86,1.15 324 53.5 1.12 0.94,1.33 316 56.9 1.27 1.06,1.52 
                
 
DBP (mmHg)
               
 
b,c
<85 mmHg 1280 62.6 Referent 
 
558 65 Referent 
 
375 61.9 Referent 
 
336 60.5 Referent 
 
≥85 mmHg 764 37.4 1.06 0.96,1.16 295 35 0.92 0.79,1.06 231 38.1 1.13 0.96,1.34 219 39.5 1.14 0.96,1.36 
                
 
d
<90 mm Hg 1568 76.7 Referent 
 
673 79 Referent 
 
453 74.8 Referent 
 
427 76.9 Referent 
 
≥ 90 mm Hg 476 23.3 1.04 0.93,1.15 180 21 0.89 0.76,1.06 153 25.3 1.21 1.00,1.46 128 23.1 1.01 0.83,1.24 
                
 
Use of antihypertensive drugs
               
 
b,c
No 1471 72.6 Referent 
 
598 71 Referent 
 
428 71.2 Referent 
 
421 76.4 Referent 
 
Yes 556 27.4 1.17 1.06,1.30 247 29 1.21 1.04,1.41 173 28.8 1.34 1.11,1.61 130 23.6 0.99 0.81,1.22 
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b,c
Hypertension definition 1  
               
 
No 447 21.9 Referent 
 
175 21 Referent 
 
146 24.1 Referent 
 
123 22.2 Referent 
 
Yes 1597 78.1 1.18 1.05,1.32 678 80 1.20 1.00,1.43 460 75.9 1.12 0.92,1.37 432 77.8 1.19 0.96,1.47 
                
 
dHypertension definition 2  
               
 
No 752 36.8 Referent 
 
308 36 Referent 
 
232 38.3 Referent 
 
207 37.3 Referent 
 
Yes 1292 63.2 1.13 1.02,1.24 545 64 1.07 0.92,1.24 374 61.7 1.15 0.96,1.38 348 62.7 1.15 0.96,1.39 
                
 
Raised fasting glucose
               
 
Glucose 
               
 
b,c
<5.6 mmol/L 1261 61.8 Referent 
 
522 61 Referent 
 
392 64.9 Referent 
 
334 60.2 Referent 
 
≥5.6 mmol/L 779 38.2 1.04 0.95,1.14 330 39 1.05 0.91,1.21 212 35.1 0.94 0.79,1.11 221 39.8 1.11 0.93,1.32 
                
 
d<6.1 mmol/L 1582 77.6 Referent 
 
658 77 Referent 
 
473 78.3 Referent 
 
431 77.7 Referent 
 
≥6.1 mmol/L 458 22.4 1.03 0.93,1.14 194 23 1.04 0.88,1.22 131 21.7 1.02 0.84,1.24 124 22.3 1.01 0.83,1.24 
                
 
Prevalent type 2 diabetes
               
 
No 1901 94 Referent 
 
796 93 Referent 
 
575 94.9 Referent 
 
522 94.1 Referent 
 
Yes 122 6 1.36 1.13,1.64 57 6.7 1.49 1.14,1.95 31 5.1 1.21 0.84,1.74 33 5.9 1.39 0.97,1.98 
                
 
b,c
Raised glucose
               
 
No 1245 60.9 Referent 
 
513 60 Referent 
 
388 64 Referent 
 
330 59.5 Referent 
 
Yes 799 39.1 1.05 0.96,1.15 340 40 1.07 0.93,1.23 218 36 0.95 0.80,1.12 225 40.5 1.12 0.94,1.33 
a adjusted for age, sex, smoking, alcohol consumption, physical activity, education, history of family cancer, and body mass index (BMI) when appropriate. BMI was presented as kg/m2 ; 
bsingle component defined by IDF (International Diabetes Federation); c single component defined by ATP III (the National Cholesterol Education Program’s Adult Treatment Panel III); d single 
component defined by the World Health Organization standard.  
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Table 4: Association of metabolic syndrome (IDF
a 
 or ATP III 
b
 definition, respectively) with risk of colorectal adenocarcinoma by anatomical locations in 
CONOR, Norway, 1995-2010 
Metabolic syndrome 
definition 
Colorectum Proximal Colon Distal Colon Rectum 
No. HR
c
 95%CI
c
 No. HR
c
 95%CI
c
 No. HR
c
 95%CI
c
 No. HR
c
 95%CI
c
 
IDF definition 
            
Total 
            
No 1117 Referent 436 Referent 
 
349 Referent 
 
313 Referent 
 
Yes 927 1.24 1.13,1.36 417 1.36 1.19,1.56 257 1.14 0.97,1.35 242 1.20 1.01,1.42 
Men 
            
No 608 Referent 208 Referent 
 
187 Referent 
 
202 Referent 
 
Yes 493 1.28 1.13,1.44 202 1.51 1.24,1.84 145 1.24 0.99,1.55 140 1.09 0.88,1.36 
Women 
            
No 509 Referent 228 Referent 
 
162 Referent 
 
111 Referent 
 
Yes 434 1.22 1.06,1.39 215 1.24 1.02,1.51 112 1.07 0.83,1.38 102 1.42 1.07,1.89 
             
ATP III definition 
            
Total 
            
No 1221 Referent 486 Referent 
 
378 Referent 
 
340 Referent 
 
Yes 823 1.17 1.07,1.28 367 1.27 1.10,1.46 228 1.09 0.94,1.29 215 1.12 0.94,1.33 
Men 
            
No 650 Referent 225 Referent 
 
200 Referent 
 
218 Referent 
 
Yes 451 1.18 1.05,1.34 185 1.40 1.15,1.70 132 1.15 0.92,1.43 125 0.98 0.79,1.23 
Women 
            
No 571 Referent 261 Referent 
 
178 Referent 
 
122 Referent 
 
Yes 372 1.18 1.03,1.36 182 1.17 0.96,1.43 96 1.07 0.82,1.38 90 1.43 1.08,1.90 
aIDF: the International Diabetes Federation; bATP III: the National Cholesterol Education Program’s Adult Treatment Panel III; cadjusted for age, sex, smoking, alcohol consumption, physical 
activity, education and history of family cancer. HR: hazard ratio; CI: confidence interval.  
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Table 5: Association of metabolic syndrome (IDF
a 
or/and ATP III
b 
definitions) with risk of colorectal adenocarcinoma by anatomical locations 
Metabolic syndrome 
definition 
Colorectum Proximal Colon Distal Colon Rectum 
No. HR
c
 95%CI
c
 No. HR
c
 95%CI
c
 No. HR
c
 95%CI
c
 No. HR
c
 95%CI
c
 
Total 
            None 989 Referent 
 
383 Referent 
 
316 Referent 
 
276 Referent 
 
Either IDF or ATP III
 d
 360 1.10 0.97, 1.24 156 1.22 1.01,1.47 95 0.93 0.74,1.17 101 1.08 0.86,1.36 
IDF and ATP III
 e
 695 1.26 1.14,1.40 314 1.40 1.20,1.63 195 1.16 0.97,1.40 178 1.20 0.99,1.46 
             Men 
            None 512 Referent 
 
175 Referent 
 
161 Referent 
 
170 Referent 
 
Either IDF or ATP III
 d
 234 1.12 0.96,1.31 83 1.16 0.89,1.51 65 1.01 0.75,1.34 81 1.17 0.90,1.53 
IDF and ATP III
 e
 355 1.31 1.14,1.51 152 1.63 1.30,2.03 106 1.27 0.99,1.63 92 1.03 0.79,1.33 
             Women 
            None 477 Referent 
 
208 Referent 
 
155 Referent 
 
106 Referent 
 
Either IDF or ATP III
 d
 126 1.09 0.89,1.33 73 1.34 1.02,1.76 30 0.86 0.58,1.28 20 0.82 0.51,1.33 
IDF and ATP III
 e
 340 1.24 1.07,1.44 162 1.24 1.00,1.54 89 1.09 0.83,1.44 86 1.52 1.13,2.06 
a 
IDF: the International Diabetes Federation; 
b
 ATP III: the National Cholesterol Education Program’s Adult Treatment Panel III; 
c
 adjusted for age, sex, smoking, alcohol consumption, 
physical activity, education, history of family cancer, and body mass index when appropriate. HR(95%CI): hazard ratio and 95% confidence interval; 
d 
Metabolic syndrome was defined by any 
of IDF or ATP III definition; e Metabolic syndrome was defined by both of IDF and ATPIII definition. 
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Figure 1. Categories of metabolic syndrome with central obesity by definition of IDF (the International Diabetes Federation definition) and risk 
of colorectal adenocarcinoma in CONOR, Norway,1995-2010. 
Remarks: A) total participants, B) Men, C) Women; HR: Hazard ratio; CI: confidence interval; Ref: reference. 
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Figure 2. Categories of metabolic syndrome with central obesity by definition of ATP III (the National Cholesterol Education Program’s Adult 
Treatment Panel III) and risk of colorectal adenocarcinoma in CONOR, Norway,1995-2010.  
Remarks: A) total participants, B) Men, C) Women; HR: Hazard ratio; CI: confidence interval; Ref: reference. 
 
